PL3725810T3 - Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego - Google Patents

Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego

Info

Publication number
PL3725810T3
PL3725810T3 PL20163993.7T PL20163993T PL3725810T3 PL 3725810 T3 PL3725810 T3 PL 3725810T3 PL 20163993 T PL20163993 T PL 20163993T PL 3725810 T3 PL3725810 T3 PL 3725810T3
Authority
PL
Poland
Prior art keywords
claudyn
malignancy
antibodies
treatment
combination therapy
Prior art date
Application number
PL20163993.7T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Rita Mitnacht-Kraus
Stefan Denis JACOBS
Magdalena Jadwiga UTSCH
Cornelia Adriana Maria HEINZ
Christiane Regina STADLER
Original Assignee
Astellas Pharma Inc.
Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48651960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3725810(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc., Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Astellas Pharma Inc.
Publication of PL3725810T3 publication Critical patent/PL3725810T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL20163993.7T 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego PL3725810T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/002211 WO2013174404A1 (en) 2012-05-23 2012-05-23 Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number Publication Date
PL3725810T3 true PL3725810T3 (pl) 2022-09-05

Family

ID=48651960

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20163993.7T PL3725810T3 (pl) 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu złośliwego

Country Status (24)

Country Link
US (5) US9433675B2 (pl)
JP (6) JP6203830B2 (pl)
KR (4) KR102810919B1 (pl)
CN (3) CN107050460B (pl)
AR (1) AR091131A1 (pl)
AU (4) AU2013265637B8 (pl)
BR (1) BR112014028941B8 (pl)
ES (2) ES2784855T3 (pl)
HK (1) HK1208151A1 (pl)
HR (1) HRP20220897T8 (pl)
HU (1) HUE059241T2 (pl)
IL (3) IL276434B2 (pl)
LT (1) LT3725810T (pl)
MX (5) MX367241B (pl)
NZ (1) NZ701575A (pl)
PL (1) PL3725810T3 (pl)
PT (1) PT3725810T (pl)
RS (1) RS63437B1 (pl)
RU (1) RU2662066C2 (pl)
SG (2) SG11201406963RA (pl)
SI (1) SI3725810T1 (pl)
SM (1) SMT202200325T1 (pl)
UA (1) UA115985C2 (pl)
WO (2) WO2013174404A1 (pl)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20100183558A1 (en) 2008-10-17 2010-07-22 Zhennan Lai Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4119582A1 (en) 2012-05-23 2023-01-18 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2016212777B2 (en) 2015-01-27 2021-11-18 LAVA Therapeutics N.V. Single domain antibodies targeting CD1d
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016165765A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis
GB201507368D0 (en) * 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2017007994A1 (en) 2015-07-08 2017-01-12 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
CA2997547A1 (en) * 2015-09-03 2017-03-09 The Uab Research Foundation Genetically-engineered drug resistant t cells and methods of using the same
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN111569090A (zh) 2016-01-15 2020-08-25 美国基因技术国际有限公司 用于活化γ-δ T细胞的方法和组合物
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Ｈｉｖワクチン接種および免疫療法
ES2911448T3 (es) * 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
US11976292B2 (en) 2016-06-08 2024-05-07 American Gene Technologies International Inc. Non-integrating viral delivery system and methods related thereto
EP3481418A4 (en) 2016-07-08 2020-03-11 American Gene Technologies International Inc. PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV
US11583562B2 (en) 2016-07-21 2023-02-21 American Gene Technologies International Inc. Viral vectors for treating Parkinson's disease
JP2020512815A (ja) 2017-04-03 2020-04-30 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド フェニルケトン尿症を処置するための組成物および方法
WO2018232359A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
CN107177549A (zh) * 2017-06-29 2017-09-19 青岛麦迪赛斯医疗技术有限公司 一种简单高效的扩增γδT细胞的方法
JP7381083B2 (ja) * 2017-09-08 2023-11-15 フォスプラティン テラピューティクス インコーポレイテッド 免疫調節剤としてのホスファプラチン化合物およびその治療的使用
SG11202007055QA (en) * 2018-03-08 2020-09-29 Phanes Therapeutics Inc Anti-claudin 18.2 antibodies and uses thereof
BR112020014591A2 (pt) 2018-03-14 2020-12-01 Beijing Xuanyi Pharmasciences Co., Ltd. anticorpos anticlaudina 18.2
CN116178555B (zh) * 2018-05-18 2025-09-09 礼新医药科技(上海)有限公司 抗密蛋白18.2抗体及其用途
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
EP3878863A4 (en) * 2018-08-27 2022-06-22 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-CLAUDIN18.2 ANTIBODIES AND ITS USE
BR112021005184A8 (pt) 2018-09-19 2022-08-16 Lava Therapeutics B V Imunoglobulina cd1d de dupla ação
EP3858384A4 (en) * 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
JP7458399B2 (ja) * 2018-12-07 2024-03-29 ゼットリップ ホールディング リミテッド 抗クローディン抗体及びそれらの使用
EP3902839A4 (en) * 2018-12-28 2022-12-14 Nanjing GenScript Biotech Co., Ltd. 18.2 CLAUDINE BINDING FRACTIONS AND THEIR USES
CN113166246B (zh) * 2018-12-28 2024-10-18 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
CN113227135B (zh) * 2018-12-28 2025-03-21 斯帕克斯治疗公司 用于治疗癌症和其他疾病的对紧密连接蛋白18.2具有特异性的结合分子、其组合物和方法
CN116333141B (zh) * 2019-01-15 2025-10-03 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
JP2022527173A (ja) * 2019-03-29 2022-05-31 フェインズ セラピューティクス，インコーポレーテッド ヒト化抗クローディン１８．２キメラ抗原受容体及びその使用
CN117264059A (zh) * 2019-05-16 2023-12-22 启愈生物技术(上海)有限公司 抗cldn抗体及其药物组合物和检测方法
JP7407841B2 (ja) 2019-05-16 2024-01-04 斉魯制薬有限公司 クローディン１８ａ２に対する抗体及びその応用
CA3141504A1 (en) 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
CN114127109B (zh) * 2019-05-30 2022-06-21 山东博安生物技术股份有限公司 靶向Claudin18.2的抗体或嵌合抗原受体
WO2021024020A1 (en) * 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN113166265B (zh) 2019-08-12 2024-06-04 天境生物科技(上海)有限公司 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途
EP4039702A1 (en) * 2019-09-16 2022-08-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-b7-h3 antibody and application thereof
CN112574307B (zh) * 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
CN112707965A (zh) * 2019-09-30 2021-04-27 和铂医药(苏州)有限公司 靶向cldn18.2的抗体及其制备方法和应用
EP4069738A1 (en) 2019-12-06 2022-10-12 SOTIO Biotech a.s. Humanized cldn18.2 antibodies
CN114761433B (zh) * 2019-12-11 2025-07-29 上海复宏汉霖生物技术股份有限公司 一种抗Claudin18.2单克隆抗体、其制备方法及用途
WO2021129927A1 (en) 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
AU2020410998A1 (en) 2019-12-23 2022-06-16 Sotio Biotech A.S. Tumor-specific Claudin 18.2 antibodies
IL298184A (en) * 2020-05-15 2023-01-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Antibody drug conjugate, preparation method therefor and use thereof
IL299748A (en) 2020-07-08 2023-03-01 Lava Therapeutics N V Antibodies that bind PSMA and T gamma delta receptors
CN111705085B (zh) * 2020-08-20 2020-12-25 北京百奥赛图基因生物技术有限公司 构建动物模型的方法及应用
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
JP2022061640A (ja) * 2020-10-07 2022-04-19 株式会社村田製作所 積層セラミックコンデンサ
WO2022100590A1 (zh) * 2020-11-10 2022-05-19 齐鲁制药有限公司 针对密蛋白18a2的adcc增强型人源化抗体及其应用
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CN116635085A (zh) 2020-12-23 2023-08-22 斯迪安生物技术公司 肿瘤特异性密蛋白18.2抗体-药物缀合物
CA3235119A1 (en) * 2021-10-19 2023-04-27 Mingjiu Chen Antibodies binding cldn18.2 and uses thereof
WO2023078386A1 (zh) * 2021-11-05 2023-05-11 正大天晴药业集团股份有限公司 抗cldn18.2抗体及其用途
CN116162168A (zh) 2021-11-25 2023-05-26 信达细胞制药(苏州)有限公司 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
IL317222A (en) * 2022-06-01 2025-01-01 Integral Molecular Inc Claudin 18.2 antibodies, methods for their preparation and uses
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
CN120981252A (zh) 2023-02-14 2025-11-18 博尔特生物治疗药物有限公司 氮杂-苯并氮杂䓬免疫缀合物及其用途
WO2026050213A1 (en) 2024-08-27 2026-03-05 Usbolt Biotherapeutics, Inc. Tlr agonist immunoconjugates and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000012708A2 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
EP1144629A3 (en) 1998-09-01 2001-11-28 Genentech, Inc. Further pro polypeptides and sequences thereof
IL142012A0 (en) 1998-09-16 2002-03-10 Zymogenetics Inc Stomach polypeptide zsig28
EP1119620A2 (en) 1998-10-06 2001-08-01 Curagen Corporation Polynucleotides coding for secreted polypeptides. some having similarity to syncollin or claudin or cytokine. their therapeutic uses
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
CA2380355A1 (en) 1999-09-01 2001-03-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6380362B1 (en) 1999-12-23 2002-04-30 Genesis Research & Development Corporation Ltd. Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use
WO2001055321A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
EP1255777A1 (en) 2000-01-31 2002-11-13 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055326A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2396719A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. 22 human secreted proteins
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001260847A1 (en) 2000-05-24 2001-12-03 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
ES2284678T3 (es) 2000-08-15 2007-11-16 Immunex Corporation Polipeptidos de claudinas.
EP1328635A2 (en) 2000-08-28 2003-07-23 Diadexus, Inc. Compositions and methods relating to lung specific genes
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR20110017020A (ko) 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
RU2006136790A (ru) * 2004-04-16 2008-05-27 Эмисфире Текнолоджис, Инк. (Us) 8-(2-гидроксифенокси)октилдиетаноламин и его соли для доставки активных агентов
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
WO2007027867A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1930414B1 (en) * 2005-09-08 2012-07-18 Medinet Co., Ltd. Method for activation treatment of antigen-presenting cell
ES2494843T3 (es) 2005-09-19 2014-09-16 Janssen Diagnostics, Llc Métodos y materiales para identificar el origen de un carcinoma de origen primario desconocido
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PT1976880T (pt) * 2005-12-21 2016-09-28 Amgen Res Munich Gmbh Composições farmacêuticas com resistência a cea solúvel
WO2008013948A2 (en) 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2125034A4 (en) 2007-02-01 2010-01-27 Veridex Llc METHOD AND MATERIALS FOR IDENTIFYING THE ORIGIN OF A CARCINOMA OF UNKNOWN PRIMARY ORIGIN
EP2145902A3 (en) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008152822A1 (ja) * 2007-06-15 2008-12-18 Medinet Co., Ltd. 医薬
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
EP2036987A1 (en) 2007-09-17 2009-03-18 Siemens Healthcare Diagnostics GmbH Molecular markers for tumor cell content in tissue samples
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
KR20110018930A (ko) 2008-06-02 2011-02-24 엔에스에이비피 파운데이션, 인크. 암 치료에서 예후적 및 예견적 마커의 확인 및 용도
US8445219B2 (en) 2008-07-25 2013-05-21 Merck Patent Gmbh Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2010141093A2 (en) * 2009-06-04 2010-12-09 The University Of Maryland, Baltimore Co-signaling methods for treating cancers
WO2011090005A1 (ja) * 2010-01-19 2011-07-28 協和発酵キリン株式会社 大腸癌の治療用医薬および治療方法
JP6199036B2 (ja) 2010-03-16 2017-09-20 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
CN102168067B (zh) * 2011-02-11 2012-08-29 浙江大学 一种调节性t细胞的诱导培养方法
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6241403B2 (ja) 2014-10-24 2017-12-06 横浜ゴム株式会社 リン酸変性ポリマー

Also Published As

Publication number Publication date
IL235672B (en) 2020-08-31
WO2013174509A1 (en) 2013-11-28
BR112014028941B1 (pt) 2019-11-12
IL318824A (en) 2025-04-01
AU2013265637A1 (en) 2014-11-20
KR102514338B1 (ko) 2023-03-28
IL276434A (en) 2020-09-30
KR20200140387A (ko) 2020-12-15
JP2025093926A (ja) 2025-06-24
PT3725810T (pt) 2022-08-01
JP6490763B2 (ja) 2019-03-27
JP6833885B2 (ja) 2021-02-24
US20240335533A1 (en) 2024-10-10
US9433675B2 (en) 2016-09-06
HK1208151A1 (en) 2016-02-26
MX2014014215A (es) 2015-06-23
NZ701575A (en) 2016-10-28
RS63437B1 (sr) 2022-08-31
JP2015518838A (ja) 2015-07-06
SG10201609510UA (en) 2016-12-29
CN107412773A (zh) 2017-12-01
US20180326059A1 (en) 2018-11-15
JP7204791B2 (ja) 2023-01-16
IL276434B1 (en) 2025-03-01
MX2020011795A (es) 2020-12-07
JP2023038230A (ja) 2023-03-16
CN107050460A (zh) 2017-08-18
BR112014028941A2 (pt) 2016-10-25
ES2784855T3 (es) 2020-10-01
US20150157711A1 (en) 2015-06-11
SI3725810T1 (sl) 2022-10-28
KR20230047493A (ko) 2023-04-07
RU2018124328A (ru) 2019-03-12
CN104427999B (zh) 2017-01-18
CN107050460B (zh) 2021-06-22
IL235672A0 (en) 2015-01-29
UA115985C2 (uk) 2018-01-25
KR20250077600A (ko) 2025-05-30
BR112014028941B8 (pt) 2020-03-17
HRP20220897T8 (hr) 2022-11-11
KR102188001B1 (ko) 2020-12-07
US20160339101A1 (en) 2016-11-24
ES2924023T3 (es) 2022-10-04
AU2013265637B2 (en) 2017-12-21
AU2013265637B8 (en) 2018-04-26
KR102810919B9 (ko) 2026-03-09
AU2023200682A1 (en) 2023-04-27
MX2020011768A (es) 2020-11-24
US20200390887A1 (en) 2020-12-17
MX367241B (es) 2019-08-09
AU2020203557A1 (en) 2020-06-18
SG11201406963RA (en) 2014-12-30
JP2021080262A (ja) 2021-05-27
JP2019104747A (ja) 2019-06-27
CN107412773B (zh) 2021-04-06
AR091131A1 (es) 2015-01-14
JP6203830B2 (ja) 2017-09-27
CA2874028A1 (en) 2013-11-28
AU2018201856A1 (en) 2018-04-12
RU2662066C2 (ru) 2018-07-23
KR20150027112A (ko) 2015-03-11
RU2018124328A3 (pl) 2021-10-22
HRP20220897T1 (hr) 2022-10-14
US10813996B2 (en) 2020-10-27
SMT202200325T1 (it) 2022-09-14
JP2018002724A (ja) 2018-01-11
WO2013174404A1 (en) 2013-11-28
IL276434B2 (en) 2025-07-01
LT3725810T (lt) 2022-08-25
MX2020011796A (es) 2020-12-07
AU2018201856B2 (en) 2020-06-18
MX2019009441A (es) 2019-12-16
HUE059241T2 (hu) 2022-11-28
RU2014152107A (ru) 2016-07-10
CN104427999A (zh) 2015-03-18
US12059464B2 (en) 2024-08-13
US10022444B2 (en) 2018-07-17
HK1247567A1 (zh) 2018-09-28
KR102810919B1 (ko) 2025-05-26

Similar Documents

Publication Publication Date Title
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL239981B1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
LT2825558T (lt) Derinių terapija, skirta kiaušidžių vėžiui gydyti
SI2852408T1 (sl) Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka
SMT202200458T1 (it) Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti